SSGJ-707
Product Specifications
Target
PD-1/PD-L1, VEGFR
Related Pathways
Apoptosis, Tyrosine Kinase/Adaptors, Angiogenesis, Immunology/Inflammation, Cell Cycle/Checkpoint
Bioactivity
SSGJ-707 is a bispecific recombinant humanized IgG4 monoclonal antibody inhibitor that targets PD-1 and VEGF. It is applicable in cancer research, particularly for advanced non-small cell lung cancer (NSCLC) and recurrent endometrial cancer.
Shipping Conditions
Ice Packs
Storage Temperature
-20°C
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog